Takeda Uses Foreign Employees To Steer Focus To Global Development
This article was originally published in PharmAsia News
Takeda Pharmaceutical is taking a new look at its business, increasing its focus on global drug development by using foreign talent to steer a staff focus on the global market.
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.